Thomas VanCott, Ph.D.

Thomas VanCott is Chairman of Board of Directors at BioViros and has been involved in virus and biologic product development for over 25 years.

VanCott is currently the Chief Scientific Officer for a Boston based biotech company developing targeted mRNA therapies. Prior to this he served as the Chief Technology and Strategy Officer for Catalent Cell & Gene Therapy, a global CDMO manufacturing viral vectors for gene and cell therapies as wells as plasmid DNA and mRNA platforms based in Baltimore, MD. 

Dr. VanCott was responsible for strategically enhancing and augmenting CMC services to meet the market demand of increasingly complex gene therapy products as well as leading the product development and internal R&D teams. Prior to this, Tom was the CEO for 10 years at a Maryland-based CMO/CRO (ABL) where he was responsible for the strategic international growth of the company.